posted on 2019-10-07, 14:46authored byKatherine A. Forrest, Tony Pham, Sameh K. Elsaidi, Mona H. Mohamed, Praveen K. Thallapally, Michael J. Zaworotko, Brian Space
A combined Monte Carlo (MC) simulation and periodic density functional theory
(DFT) study of CO2 sorption was performed in SIFSIX-3-M (M = Fe, Co, Ni, Cu, Zn),
a family of hybrid ultramicroporous materials (HUMs) that consists of M2+ ions coordinated to
pyrazine ligands and are pillared with SiF6
2 (\SIFSIX") anions. Grand canonical Monte Carlo
(GCMC) simulations of CO2 sorption in all ve SIFSIX-3-M variants produced isotherms that are
in good agreement with the corresponding experimental measurements. The theoretical isosteric
heat of adsorption (Qst) for CO2 as obtained through canonical Monte Carlo (CMC) simulations are
also in close agreement with the experimental values. Consistent with experiment, the simulations
generated the following trend in the CO2 Qst: SIFSIX-3-Cu > SIFSIX-3-Ni > SIFSIX-3-Co >
SIFSIX-Zn > SIFSIX-3-Fe. The magnitudes of the theoretical Qst and relative trend were further
supported by periodic DFT calculations of the adsorption energy for CO2 within the respective
HUMs. We attribute the observed Qst trend in SIFSIX-3-M to their di erences in pore size and
lattice parameters. Speci cally, the sorption energetics decrease with increasing pore size and a/b
lattice constant. Simulations of CO2 sorption in SIFSIX-3-Cu resulted in di erent pro les for the
radial distribution function (g(r)) and dipole distribution than within the other analogues due to
the smaller pore size and much shorter a/b unit cell lengths of the crystal structure; this is a direct
consequence of the Jahn{Teller e ect. Although these HUMs are isostructural, notable di erences
in the classical energy contributions for CO2 sorption were observed from the GCMC simulations.
Overall, this study demonstrates that the CO2 Qst in SIFSIX-3-M can be controlled by the choice
of the saturated metal, with values ranging from 42 to 54 kJ mol-1.
Funding
Prostate specific antigen (PSA) in benign prostate hyperplasia (BPH) and prostate cancer